Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
41 hedge funds and large institutions have $130M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 41 → 41 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
45% less capital invested
Capital invested by funds: $235M → $130M (-$105M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$794K |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$262K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$250K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$160K |
| 5 |
Morgan Stanley
New York
|
+$91.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.61M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$543K |
| 3 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
-$323K |
| 4 |
Two Sigma Investments
New York
|
-$145K |
| 5 |
Two Sigma Advisers
New York
|
-$107K |
FUSN Hedge Fund Activity: Q3 2023 in Review
41 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q3 2023, worth a combined $130M — down 45% from $235M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FUSN positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, adding an estimated $794K. The largest seller was Fidelity Investments, cutting an estimated $1.61M.
- 41 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $130M of Fusion Pharmaceuticals Inc. Common Shares stock for Q3 2023, down 45% quarter-over-quarter.
- 4 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q3 2023 and 3 closed out, a net change of +1 holder.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q3 2023 was Millennium Management, an estimated $794K added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q3 2023 was Fidelity Investments, an estimated $1.61M sold.
Based on aggregated 13F filings for Q3 2023.